Zbigniew Zasłona

Immunology and Microbiology · Life Sciences

29h-index4.7kcitations142works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune cells in cancer(61), Cancer Research and Treatments(44), Adenosine and Purinergic Signaling(37), Receptor Mechanisms and Signaling(17), Studies on Chitinases and Chitosanases(13)

Publications142 total

Low-resolution electron density map of the druggable 5'3WJ of IL-2 RNA
Mendeley Data·2026Open Access
Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 16 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 22 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
2025Open Access
Mendelian randomization to inform a clinical trial of chitotriosidase inhibition for pulmonary sarcoidosis
2025Open Access
Elucidation of the Catalytic Apparatus and Mechanism of Human Chitotriosidase-1
ACS Catalysis·2025· 1 citedOpen Access
Therapeutic inhibition of USP7 promotes antitumor immune responses
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models
Frontiers in Immunology·2025· 1 citedOpen Access
Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity
Scientific Reports·2025· 8 citedOpen Access
Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity
2025Open Access
page 1 of 8Next →

Frequent Co-authors

Luke O'neill(19), Marc Peters‐Golden(15), Eva M. Pålsson‐McDermott(6), Adam Gołȩbiowski(6), Kingston H. G. Mills(5), Marcin Grzybowski(5), Tomasz Rejczak(5), Michał Mlącki(5), Katarzyna Drzewicka(5), Dylan G. Ryan(4), Deepthi Menon(4), Anne F. McGettrick(4), Richard G. Carroll(4), Sarah E. Corcoran(4), Annie M. Curtis(4), Emilie Bourdonnay(4), Loka R. Penke(4), Jennifer M. Speth(4), Sally Przybranowski(4), Peter Mancuso(4)